Zylox-Tonbridge Medical Technology Co., Ltd.

HKSE 2190.HK

Zylox-Tonbridge Medical Technology Co., Ltd. Receivables for the year ending December 31, 2023: USD 166.48 K

Zylox-Tonbridge Medical Technology Co., Ltd. Receivables is USD 166.48 K for the year ending December 31, 2023, a 13.30% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Receivables for the year ending December 31, 2022 was USD 146.94 K, a 109.34% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Receivables for the year ending December 31, 2021 was USD 70.19 K, a 255.17% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Receivables for the year ending December 31, 2020 was USD 19.76 K, a -86.41% change year over year.
  • Zylox-Tonbridge Medical Technology Co., Ltd. Receivables for the year ending December 31, 2019 was USD 145.47 K.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
Loading...
SV Wall Street
HKSE: 2190.HK

Zylox-Tonbridge Medical Technology Co., Ltd.

CEO Dr. Zhong Zhao Ph.D.
IPO Date July 5, 2021
Location China
Headquarters Building 1
Employees 756
Sector Health Care
Industries
Description

Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.

Similar companies

2162.HK

Keymed Biosciences Inc.

USD 3.88

-0.18%

2170.HK

Suzhou Basecare Medical Corporation Limited

USD 0.36

3.69%

StockViz Staff

January 31, 2025

Any question? Send us an email